Abstract
Our case studies from three Scandinavian countries have shown that parallel trade is not lowering drug expenditures to the same extent in all countries. While relative price advantages of parallel traded drugs are sizeable in Sweden, they are very low in Norway.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag AG
About this chapter
Cite this chapter
(2008). Increasing payers benefits from parallel trade: Observations from Scandinavia and policy proposals for Europe. In: Parallel Imports of Pharmaceuticals. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8589-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8589-7_5
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8588-0
Online ISBN: 978-3-7643-8589-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)